Copyright
©The Author(s) 2019.
World J Clin Cases. Aug 26, 2019; 7(16): 2189-2203
Published online Aug 26, 2019. doi: 10.12998/wjcc.v7.i16.2189
Published online Aug 26, 2019. doi: 10.12998/wjcc.v7.i16.2189
Table 1 Clinical characteristics of all subjects, n (%)
Clinicopathological features | UC, n = 40 | CD, n = 97 | HCs, n = 50 |
Male | 26 (65) | 69 (71.13) | 30 (60) |
Female | 14 (35) | 28 (28.87) | 20 (40) |
Age in yr, mean ± SD | 34.22 ± 12.50 | 33.51 ± 11.77 | 36.2 ± 10.73 |
Duration of disease in yr, mean, 95%CI | 3.69 (2.12-4.86) | 2.80 (2.01-3.54) | / |
Disease activity | |||
Remission | 10 (25) | 37 (38.14) | / |
Mild | 6 (15) | 36 (37.11) | / |
Moderate | 17 (42.5) | 23 (23.71) | / |
Severe | 7 (17.5) | 1 (1.04) | / |
Age at diagnosis in yr | |||
A1, ≤ 16 | / | 6 (6.19) | / |
A2, 17-40 | / | 67 (69.07) | / |
A3, > 40 | / | 24 (24.74) | / |
Disease location | |||
L1, terminal ileum | / | 41 (42.27) | / |
L2, colon | / | 17 (17.53) | / |
L3, ileocolon | / | 33 (34.02) | / |
L1+L4 | / | 3 (3.09) | / |
L3+L4 | / | 3 (3.09) | / |
E1, rectum | 10 (25) | / | |
E2, left-sided colon | 7 (17.5) | / | |
E3, entire colon | 23 (57.5) | / | |
Disease behaviour | |||
B1, non-stricturing, non-penetrating | 58 (59.79) | / | |
B2, stricturing | 32 (32.98) | / | |
B3, penetrating | 6 (6.19) | / | |
B2 + B3 | 1 (1.04) | / | |
CDAI, mean ± SD | 153.96 ± 80.22 | ||
Mayo, mean ± SD | 6.52 ± 3.24 | ||
Smoker | 10 (25) | 8 (8.25) | / |
Perianal diseases | 1 (2.5) | 5 (5.15) | / |
Medications | |||
5-ASA | 32 (80) | 31 (31.96) | / |
Sulfasalazine | 2 (5) | / | / |
Steroids | 10 (25) | 9 (9.28) | / |
Immunosuppressive agents | 2 (5) | 19 (19.59) | / |
Anti-TNF | / | 32 (32.99) | / |
Enteral nutrition | / | 18 (18.56) | |
No meds | 4 (10) | / | / |
Surgery, IBD-related | 2 (5) | 30 (30.93) | / |
Table 2 Percentage of positive food-specific IgG antibodies against 14 food items in ulcerative colitis patients, Crohn’s disease patients, and healthy controls
Table 3 Comparison of laboratory results between positive and negative food-specific IgG subgroups in inflammatory bowel disease patients
Laboratory results | sIgG (+) | sIgG (-) | P-value |
n = 111 | n = 26 | ||
WBC, × 109/L | 6.56 ± 2.57 | 6.26 ± 2.17 | 0.62 |
Hb, g/L | 121.59 ± 23.72 | 123.71 ± 29.27 | 0.77 |
HCT | 38.45 ± 6.38 | 37.36 ± 6.14 | 0.83 |
PLT, × 109/L | 280.75 ± 110.31 | 233.65 ± 86.34 | 0.13 |
CRP, mg/L | 17.27 ± 6.64 | 11.17 ± 4.84 | 0.13 |
ESR, mm/H | 21.49 ± 19.88 | 20.12 ± 19.40 | 0.64 |
ALB, g/L | 37.08 ± 5.24 | 40.21 ± 5.23 | 0.16 |
Table 4 Correlation between food-specific IgG and clinical parameters
- Citation: Wang HY, Li Y, Li JJ, Jiao CH, Zhao XJ, Li XT, Lu MJ, Mao XQ, Zhang HJ. Serological investigation of IgG and IgE antibodies against food antigens in patients with inflammatory bowel disease. World J Clin Cases 2019; 7(16): 2189-2203
- URL: https://www.wjgnet.com/2307-8960/full/v7/i16/2189.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v7.i16.2189